Non-Hodgkin lymphoma is not a single disease: it is a group of more than 85 related blood cancers that vary widely in how they grow, spread, and respond to treatment. This resource provides a broad overview of NHL, covering risk factors, how it is diagnosed and staged, and the range of treatment options available across subtypes. It is a strong starting point for anyone newly diagnosed or looking to better understand the landscape of NHL.
Entendiendo: Los estudios clínicos para el linfoma Download © 2026 Lymphoma Research Foundation Última actualización en 2023 La Lymphoma Research Foundation (LRF) publica la serie de hojas informativas Comprender el linfoma con el propósito de informar y educar a los…
Clinical trials are how new lymphoma treatments get developed, tested, and approved, and they are far from a last resort. This resource explains how clinical trials work, what the different phases mean, and what patients can expect if they choose to participate. It also covers informed consent, costs, insurance coverage, and questions to ask before enrolling, along with guidance on how to find trials through LRF's Clinical Trials Information Service.
Chemotherapy remains one of the most widely used treatments for lymphoma, working by targeting the rapid growth and division of cancer cells throughout the body. This resource explains how chemotherapy works, how it is administered, and why sticking to the treatment schedule matters. It also includes a comprehensive reference table of common chemotherapy regimens used for both Hodgkin and non-Hodgkin lymphoma, along with what patients can expect during and after treatment.
Los Anticuerpos Biespecíficos Entendiendo el Linfoma y la LLC Download © 2024 Lymphoma Research Foundation Última actualización en mayo de 2024 Lymphoma Research Foundation publica la serie de hojas informativas Entendiendo el Linfoma y la LLC con el propósito de…
Bispecific antibodies are an emerging class of immunotherapy that work by simultaneously targeting two antigens: one on the cancer cell and one on a healthy immune cell, effectively linking them together to trigger an immune response against the lymphoma. This resource explains how they work, how they differ from standard monoclonal antibodies, and which FDA-approved options are currently available for lymphoma patients. It also covers side effects to watch for, therapies under investigation, and questions to bring to your care team.
Entendiendo el linfoma de células del mantophoma Download © 2024 Lymphoma Research Foundation Última actualización en mayo de 2024 Investigación. Comunidad. Curar.Lymphoma Research Foundation publica la serie de hojas informativas Entendiendo el Linfoma y la LLC con el propósito de…
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that most commonly affects men over 60 and can range from slow-growing to increasingly aggressive over time. This resource covers how it is diagnosed and staged, the treatment options available from initial therapy through relapsed or refractory disease, and guidance on self-advocacy throughout the care journey. It also includes an overview of therapies currently under investigation and questions to bring to your healthcare team.
Entendieno los Linfomas de Linfocitos B Indolentes Download © 2025 Lymphoma Research FoundationAviso: La Lymphoma Research Foundation es una organización nacional sin fines de lucro con sede en los Estados Unidos (EE. UU.) que cuenta con programas y recursos educativos…
This resource covers three slow-growing B-cell lymphomas that, while distinct in how and where they develop, share a generally indolent course that often allows for careful monitoring before treatment begins. It walks through each subtype's symptoms, how it is diagnosed and staged, and the treatment options available from first-line therapy through relapsed or refractory disease. Guidance on self-advocacy, therapies under investigation, and questions for your healthcare team are also included.
